<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 18:55:47 -0700</creation_date>
  <update_date>2013-01-15 18:55:47 -0700</update_date>
  <accession>HMDBP01362</accession>
  <secondary_accessions>
    <accession>6658</accession>
  </secondary_accessions>
  <protein_type>Enzyme</protein_type>
  <synonyms>
    <synonym>CD333 antigen</synonym>
    <synonym>FGFR-3</synonym>
  </synonyms>
  <gene_name>FGFR3</gene_name>
  <general_function>Involved in protein kinase activity</general_function>
  <specific_function>Receptor for acidic and basic fibroblast growth factors. Preferentially binds FGF1</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00538</accession>
      <name>Adenosine triphosphate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01341</accession>
      <name>ADP</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>protein binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>protein tyrosine kinase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transmembrane receptor protein tyrosine kinase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>fibroblast growth factor receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>nucleoside binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>purine nucleoside binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>adenyl nucleotide binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>adenyl ribonucleotide binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>atp binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>catalytic activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transferase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transferase activity, transferring phosphorus-containing groups</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>kinase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>protein kinase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>signaling</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cell surface receptor linked signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>enzyme linked receptor protein signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>transmembrane receptor protein tyrosine kinase signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>fibroblast growth factor receptor signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>biological regulation</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>regulation of biological process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>regulation of cellular process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>regulation of cell proliferation</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>positive regulation of cell proliferation</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cellular metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>phosphorus metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>phosphate metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>phosphorylation</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>protein amino acid phosphorylation</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intrinsic to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>integral to membrane</description>
      <go_id/>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Membrane</subcellular_location>
    <subcellular_location>Single-pass type I membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>Chromosome:4</chromosome_location>
    <locus>4p16.3</locus>
    <gene_sequence>&gt;2421 bp
ATGGGCGCCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCCGTGGCCATCGTGGCCGGCGCC
TCCTCGGAGTCCTTGGGGACGGAGCAGCGCGTCGTGGGGCGAGCGGCAGAAGTCCCGGGC
CCAGAGCCCGGCCAGCAGGAGCAGTTGGTCTTCGGCAGCGGGGATGCTGTGGAGCTGAGC
TGTCCCCCGCCCGGGGGTGGTCCCATGGGGCCCACTGTCTGGGTCAAGGATGGCACAGGG
CTGGTGCCCTCGGAGCGTGTCCTGGTGGGGCCCCAGCGGCTGCAGGTGCTGAATGCCTCC
CACGAGGACTCCGGGGCCTACAGCTGCCGGCAGCGGCTCACGCAGCGCGTACTGTGCCAC
TTCAGTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATGACGAAGACGGGGAGGACGAG
GCTGAGGACACAGGTGTGGACACAGGGGCCCCTTACTGGACACGGCCCGAGCGGATGGAC
AAGAAGCTGCTGGCCGTGCCGGCCGCCAACACCGTCCGCTTCCGCTGCCCAGCCGCTGGC
AACCCCACTCCCTCCATCTCCTGGCTGAAGAACGGCAGGGAGTTCCGCGGCGAGCACCGC
ATTGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGGTCATGGAAAGCGTGGTGCCC
TCGGACCGCGGCAACTACACCTGCGTCGTGGAGAACAAGTTTGGCAGCATCCGGCAGACG
TACACGCTGGACGTGCTGGAGCGCTCCCCGCACCGGCCCATCCTGCAGGCGGGGCTGCCG
GCCAACCAGACGGCGGTGCTGGGCAGCGACGTGGAGTTCCACTGCAAGGTGTACAGTGAC
GCACAGCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGAACGGCAGCAAGGTGGGCCCG
GACGGCACACCCTACGTTACCGTGCTCAAGACGGCGGGCGCTAACACCACCGACAAGGAG
CTAGAGGTTCTCTCCTTGCACAACGTCACCTTTGAGGACGCCGGGGAGTACACCTGCCTG
GCGGGCAATTCTATTGGGTTTTCTCATCACTCTGCGTGGCTGGTGGTGCTGCCAGCCGAG
GAGGAGCTGGTGGAGGCTGACGAGGCGGGCAGTGTGTATGCAGGCATCCTCAGCTACGGG
GTGGGCTTCTTCCTGTTCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCCTGCGCAGC
CCCCCCAAGAAAGGCCTGGGCTCCCCCACCGTGCACAAGATCTCCCGCTTCCCGCTCAAG
CGACAGGTGTCCCTGGAGTCCAACGCGTCCATGAGCTCCAACACACCACTGGTGCGCATC
GCAAGGCTGTCCTCAGGGGAGGGCCCCACGCTGGCCAATGTCTCCGAGCTCGAGCTGCCT
GCCGACCCCAAATGGGAGCTGTCTCGGGCCCGGCTGACCCTGGGCAAGCCCCTTGGGGAG
GGCTGCTTCGGCCAGGTGGTCATGGCGGAGGCCATCGGCATTGACAAGGACCGGGCCGCC
AAGCCTGTCACCGTAGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTCG
GACCTGGTGTCTGAGATGGAGATGATGAAGATGATCGGGAAACACAAAAACATCATCAAC
CTGCTGGGCGCCTGCACGCAGGGCGGGCCCCTGTACGTGCTGGTGGAGTACGCGGCCAAG
GGTAACCTGCGGGAGTTTCTGCGGGCGCGGCGGCCCCCGGGCCTGGACTACTCCTTCGAC
ACCTGCAAGCCGCCCGAGGAGCAGCTCACCTTCAAGGACCTGGTGTCCTGTGCCTACCAG
GTGGCCCGGGGCATGGAGTACTTGGCCTCCCAGAAGTGCATCCACAGGGACCTGGCTGCC
CGCAATGTGCTGGTGACCGAGGACAACGTGATGAAGATCGCAGACTTCGGGCTGGCCCGG
GACGTGCACAACCTCGACTACTACAAGAAGACAACCAACGGCCGGCTGCCCGTGAAGTGG
ATGGCGCCTGAGGCCTTGTTTGACCGAGTCTACACTCACCAGAGTGACGTCTGGTCCTTT
GGGGTCCTGCTCTGGGAGATCTTCACGCTGGGGGGCTCCCCGTACCCCGGCATCCCTGTG
GAGGAGCTCTTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCGCCAACTGCACA
CACGACCTGTACATGATCATGCGGGAGTGCTGGCATGCCGCGCCCTCCCAGAGGCCCACC
TTCAAGCAGCTGGTGGAGGACCTGGACCGTGTCCTTACCGTGACGTCCACCGACGAGTAC
CTGGACCTGTCGGCGCCTTTCGAGCAGTACTCCCCGGGTGGCCAGGACACCCCCAGCTCC
AGCTCCTCAGGGGACGACTCCGTGTTTGCCCACGACCTGCTGCCCCCGGCCCCACCCAGC
AGTGGGGGCTCGCGGACGTGA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>806</residue_number>
    <molecular_weight>87708.9</molecular_weight>
    <theoretical_pi>5.73</theoretical_pi>
    <pfams>
      <pfam>
        <name>I-set</name>
        <pfam_id>PF07679</pfam_id>
      </pfam>
      <pfam>
        <name>ig</name>
        <pfam_id>PF00047</pfam_id>
      </pfam>
      <pfam>
        <name>Pkinase_Tyr</name>
        <pfam_id>PF07714</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
      <region>376-396</region>
    </transmembrane_regions>
    <signal_regions>
      <region>1-22</region>
    </signal_regions>
    <protein_sequence>&gt;Fibroblast growth factor receptor 3
MGAPACALALCVAVAIVAGASSESLGTEQRVVGRAAEVPGPEPGQQEQLVFGSGDAVELS
CPPPGGGPMGPTVWVKDGTGLVPSERVLVGPQRLQVLNASHEDSGAYSCRQRLTQRVLCH
FSVRVTDAPSSGDDEDGEDEAEDTGVDTGAPYWTRPERMDKKLLAVPAANTVRFRCPAAG
NPTPSISWLKNGREFRGEHRIGGIKLRHQQWSLVMESVVPSDRGNYTCVVENKFGSIRQT
YTLDVLERSPHRPILQAGLPANQTAVLGSDVEFHCKVYSDAQPHIQWLKHVEVNGSKVGP
DGTPYVTVLKTAGANTTDKELEVLSLHNVTFEDAGEYTCLAGNSIGFSHHSAWLVVLPAE
EELVEADEAGSVYAGILSYGVGFFLFILVVAAVTLCRLRSPPKKGLGSPTVHKISRFPLK
RQVSLESNASMSSNTPLVRIARLSSGEGPTLANVSELELPADPKWELSRARLTLGKPLGE
GCFGQVVMAEAIGIDKDRAAKPVTVAVKMLKDDATDKDLSDLVSEMEMMKMIGKHKNIIN
LLGACTQGGPLYVLVEYAAKGNLREFLRARRPPGLDYSFDTCKPPEEQLTFKDLVSCAYQ
VARGMEYLASQKCIHRDLAARNVLVTEDNVMKIADFGLARDVHNLDYYKKTTNGRLPVKW
MAPEALFDRVYTHQSDVWSFGVLLWEIFTLGGSPYPGIPVEELFKLLKEGHRMDKPANCT
HDLYMIMRECWHAAPSQRPTFKQLVEDLDRVLTVTSTDEYLDLSAPFEQYSPGGQDTPSS
SSSGDDSVFAHDLLPPAPPSSGGSRT</protein_sequence>
  </protein_properties>
  <genbank_protein_id>182569</genbank_protein_id>
  <uniprot_id>P22607</uniprot_id>
  <uniprot_name>FGFR3_HUMAN</uniprot_name>
  <pdb_ids>
    <pdb_id>1RY7</pdb_id>
  </pdb_ids>
  <genbank_gene_id>M58051</genbank_gene_id>
  <genecard_id>FGFR3</genecard_id>
  <geneatlas_id>FGFR3</geneatlas_id>
  <hgnc_id>HGNC:3690</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Keegan K, Johnson DE, Williams LT, Hayman MJ: Isolation of an additional member of the fibroblast growth factor receptor family, FGFR-3. Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1095-9.</reference_text>
      <pubmed_id>1847508</pubmed_id>
    </reference>
    <reference>
      <reference_text>Terada M, Shimizu A, Sato N, Miyakaze SI, Katayama H, Kurokawa-Seo M: Fibroblast growth factor receptor 3 lacking the Ig IIIb and transmembrane domains secreted from human squamous cell carcinoma DJM-1 binds to FGFs. Mol Cell Biol Res Commun. 2001 Nov;4(6):365-73.</reference_text>
      <pubmed_id>11703096</pubmed_id>
    </reference>
    <reference>
      <reference_text>Thompson LM, Plummer S, Schalling M, Altherr MR, Gusella JF, Housman DE, Wasmuth JJ: A gene encoding a fibroblast growth factor receptor isolated from the Huntington disease gene region of human chromosome 4. Genomics. 1991 Dec;11(4):1133-42.</reference_text>
      <pubmed_id>1664411</pubmed_id>
    </reference>
    <reference>
      <reference_text>Partanen J, Makela TP, Alitalo R, Lehvaslaiho H, Alitalo K: Putative tyrosine kinases expressed in K-562 human leukemia cells.  Proc Natl Acad Sci U S A. 1990 Nov;87(22):8913-7.</reference_text>
      <pubmed_id>2247464</pubmed_id>
    </reference>
    <reference>
      <reference_text>Murgue B, Tsunekawa S, Rosenberg I, deBeaumont M, Podolsky DK: Identification of a novel variant form of fibroblast growth factor receptor 3 (FGFR3 IIIb) in human colonic epithelium. Cancer Res. 1994 Oct 1;54(19):5206-11.</reference_text>
      <pubmed_id>7923141</pubmed_id>
    </reference>
    <reference>
      <reference_text>Scotet E, Houssaint E: The choice between alternative IIIb and IIIc exons of the FGFR-3 gene is not strictly tissue-specific. Biochim Biophys Acta. 1995 Nov 7;1264(2):238-42.</reference_text>
      <pubmed_id>7495869</pubmed_id>
    </reference>
    <reference>
      <reference_text>Olsen SK, Ibrahimi OA, Raucci A, Zhang F, Eliseenkova AV, Yayon A, Basilico C, Linhardt RJ, Schlessinger J, Mohammadi M: Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity. Proc Natl Acad Sci U S A. 2004 Jan 27;101(4):935-40. Epub 2004 Jan 19.</reference_text>
      <pubmed_id>14732692</pubmed_id>
    </reference>
    <reference>
      <reference_text>Rousseau F, Bonaventure J, Legeai-Mallet L, Pelet A, Rozet JM, Maroteaux P, Le Merrer M, Munnich A: Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature. 1994 Sep 15;371(6494):252-4.</reference_text>
      <pubmed_id>8078586</pubmed_id>
    </reference>
    <reference>
      <reference_text>Bellus GA, Hefferon TW, Ortiz de Luna RI, Hecht JT, Horton WA, Machado M, Kaitila I, McIntosh I, Francomano CA: Achondroplasia is defined by recurrent G380R mutations of FGFR3.  Am J Hum Genet. 1995 Feb;56(2):368-73.</reference_text>
      <pubmed_id>7847369</pubmed_id>
    </reference>
    <reference>
      <reference_text>Superti-Furga A, Eich G, Bucher HU, Wisser J, Giedion A, Gitzelmann R, Steinmann B: A glycine 375-to-cysteine substitution in the transmembrane domain of the fibroblast growth factor receptor-3 in a newborn with achondroplasia. Eur J Pediatr. 1995 Mar;154(3):215-9.</reference_text>
      <pubmed_id>7758520</pubmed_id>
    </reference>
    <reference>
      <reference_text>Tavormina PL, Rimoin DL, Cohn DH, Zhu YZ, Shiang R, Wasmuth JJ: Another mutation that results in the substitution of an unpaired cysteine residue in the extracellular domain of FGFR3 in thanatophoric dysplasia type I. Hum Mol Genet. 1995 Nov;4(11):2175-7.</reference_text>
      <pubmed_id>8589699</pubmed_id>
    </reference>
    <reference>
      <reference_text>Tavormina PL, Shiang R, Thompson LM, Zhu YZ, Wilkin DJ, Lachman RS, Wilcox WR, Rimoin DL, Cohn DH, Wasmuth JJ: Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat Genet. 1995 Mar;9(3):321-8.</reference_text>
      <pubmed_id>7773297</pubmed_id>
    </reference>
    <reference>
      <reference_text>Bellus GA, McIntosh I, Smith EA, Aylsworth AS, Kaitila I, Horton WA, Greenhaw GA, Hecht JT, Francomano CA: A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia. Nat Genet. 1995 Jul;10(3):357-9.</reference_text>
      <pubmed_id>7670477</pubmed_id>
    </reference>
    <reference>
      <reference_text>Meyers GA, Orlow SJ, Munro IR, Przylepa KA, Jabs EW: Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans. Nat Genet. 1995 Dec;11(4):462-4.</reference_text>
      <pubmed_id>7493034</pubmed_id>
    </reference>
    <reference>
      <reference_text>Webster MK, Donoghue DJ: Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. EMBO J. 1996 Feb 1;15(3):520-7.</reference_text>
      <pubmed_id>8599935</pubmed_id>
    </reference>
    <reference>
      <reference_text>Rousseau F, el Ghouzzi V, Delezoide AL, Legeai-Mallet L, Le Merrer M, Munnich A, Bonaventure J: Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1). Hum Mol Genet. 1996 Apr;5(4):509-12.</reference_text>
      <pubmed_id>8845844</pubmed_id>
    </reference>
    <reference>
      <reference_text>Muenke M, Gripp KW, McDonald-McGinn DM, Gaudenz K, Whitaker LA, Bartlett SP, Markowitz RI, Robin NH, Nwokoro N, Mulvihill JJ, Losken HW, Mulliken JB, Guttmacher AE, Wilroy RS, Clarke LA, Hollway G, Ades LC, Haan EA, Mulley JC, Cohen MM Jr, Bellus GA, Francomano CA, Moloney DM, Wall SA, Wilkie AO, et al.: A unique point mutation in the fibroblast growth factor receptor 3 gene (FGFR3) defines a new craniosynostosis syndrome. Am J Hum Genet. 1997 Mar;60(3):555-64.</reference_text>
      <pubmed_id>9042914</pubmed_id>
    </reference>
    <reference>
      <reference_text>Chesi M, Nardini E, Brents LA, Schrock E, Ried T, Kuehl WM, Bergsagel PL: Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet. 1997 Jul;16(3):260-4.</reference_text>
      <pubmed_id>9207791</pubmed_id>
    </reference>
    <reference>
      <reference_text>Katsumata N, Kuno T, Miyazaki S, Mikami S, Nagashima-Miyokawa A, Nimura A, Horikawa R, Tanaka T: G370C mutation in the FGFR3 gene in a Japanese patient with thanatophoric dysplasia. Endocr J. 1998 Apr;45 Suppl:S171-4.</reference_text>
      <pubmed_id>9790257</pubmed_id>
    </reference>
    <reference>
      <reference_text>Grigelioniene G, Hagenas L, Eklof O, Neumeyer L, Haereid PE, Anvret M: A novel missense mutation Ile538Val in the fibroblast growth factor receptor 3 in hypochondroplasia. Mutations in brief no. 122. Online. Hum Mutat. 1998;11(4):333.</reference_text>
      <pubmed_id>10215410</pubmed_id>
    </reference>
    <reference>
      <reference_text>Deutz-Terlouw PP, Losekoot M, Aalfs CM, Hennekam RC, Bakker E: Asn540Thr substitution in the fibroblast growth factor receptor 3 tyrosine kinase domain causing hypochondroplasia. Hum Mutat. 1998;Suppl 1:S62-5.</reference_text>
      <pubmed_id>9452043</pubmed_id>
    </reference>
    <reference>
      <reference_text>Kitoh H, Brodie SG, Kupke KG, Lachman RS, Wilcox WR: Lys650Met substitution in the tyrosine kinase domain of the fibroblast growth factor receptor gene causes thanatophoric dysplasia Type I. Mutations in brief no. 199. Online. Hum Mutat. 1998;12(5):362-3.</reference_text>
      <pubmed_id>10671061</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hollway GE, Suthers GK, Battese KM, Turner AM, David DJ, Mulley JC: Deafness due to Pro250Arg mutation of FGFR3.  Lancet. 1998 Mar 21;351(9106):877-8.</reference_text>
      <pubmed_id>9525367</pubmed_id>
    </reference>
    <reference>
      <reference_text>Brodie SG, Kitoh H, Lachman RS, Nolasco LM, Mekikian PB, Wilcox WR: Platyspondylic lethal skeletal dysplasia, San Diego type, is caused by FGFR3 mutations. Am J Med Genet. 1999 Jun 11;84(5):476-80.</reference_text>
      <pubmed_id>10360402</pubmed_id>
    </reference>
    <reference>
      <reference_text>Lajeunie E, El Ghouzzi V, Le Merrer M, Munnich A, Bonaventure J, Renier D: Sex related expressivity of the phenotype in coronal craniosynostosis caused by the recurrent P250R FGFR3 mutation. J Med Genet. 1999 Jan;36(1):9-13.</reference_text>
      <pubmed_id>9950359</pubmed_id>
    </reference>
    <reference>
      <reference_text>Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X, Chopin D, Thiery JP, Radvanyi F: Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet. 1999 Sep;23(1):18-20.</reference_text>
      <pubmed_id>10471491</pubmed_id>
    </reference>
    <reference>
      <reference_text>Bellus GA, Spector EB, Speiser PW, Weaver CA, Garber AT, Bryke CR, Israel J, Rosengren SS, Webster MK, Donoghue DJ, Francomano CA: Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype. Am J Hum Genet. 2000 Dec;67(6):1411-21. Epub 2000 Oct 27.</reference_text>
      <pubmed_id>11055896</pubmed_id>
    </reference>
    <reference>
      <reference_text>Mortier G, Nuytinck L, Craen M, Renard JP, Leroy JG, de Paepe A: Clinical and radiographic features of a family with hypochondroplasia owing to a novel Asn540Ser mutation in the fibroblast growth factor receptor 3 gene. J Med Genet. 2000 Mar;37(3):220-4.</reference_text>
      <pubmed_id>10777366</pubmed_id>
    </reference>
    <reference>
      <reference_text>Lowry RB, Jabs EW, Graham GE, Gerritsen J, Fleming J: Syndrome of coronal craniosynostosis, Klippel-Feil anomaly, and sprengel shoulder with and without Pro250Arg mutation in the FGFR3 gene. Am J Med Genet. 2001 Nov 22;104(2):112-9.</reference_text>
      <pubmed_id>11746040</pubmed_id>
    </reference>
    <reference>
      <reference_text>Intini D, Baldini L, Fabris S, Lombardi L, Ciceri G, Maiolo AT, Neri A: Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14). Br J Haematol. 2001 Aug;114(2):362-4.</reference_text>
      <pubmed_id>11529856</pubmed_id>
    </reference>
    <reference>
      <reference_text>Jang JH, Shin KH, Park JG: Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res. 2001 May 1;61(9):3541-3.</reference_text>
      <pubmed_id>11325814</pubmed_id>
    </reference>
    <reference>
      <reference_text>Sibley K, Cuthbert-Heavens D, Knowles MA: Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. Oncogene. 2001 Feb 8;20(6):686-91.</reference_text>
      <pubmed_id>11314002</pubmed_id>
    </reference>
    <reference>
      <reference_text>Thauvin-Robinet C, Faivre L, Lewin P, De Monleon JV, Francois C, Huet F, Couailler JF, Campos-Xavier AB, Bonaventure J, Le Merrer M: Hypochondroplasia and stature within normal limits: another family with an Asn540Ser mutation in the fibroblast growth factor receptor 3 gene. Am J Med Genet A. 2003 May 15;119A(1):81-4.</reference_text>
      <pubmed_id>12707965</pubmed_id>
    </reference>
    <reference>
      <reference_text>Logie A, Dunois-Larde C, Rosty C, Levrel O, Blanche M, Ribeiro A, Gasc JM, Jorcano J, Werner S, Sastre-Garau X, Thiery JP, Radvanyi F: Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum Mol Genet. 2005 May 1;14(9):1153-60. Epub 2005 Mar 16.</reference_text>
      <pubmed_id>15772091</pubmed_id>
    </reference>
    <reference>
      <reference_text>Toydemir RM, Brassington AE, Bayrak-Toydemir P, Krakowiak PA, Jorde LB, Whitby FG, Longo N, Viskochil DH, Carey JC, Bamshad MJ: A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome. Am J Hum Genet. 2006 Nov;79(5):935-41. Epub 2006 Sep 26.</reference_text>
      <pubmed_id>17033969</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hafner C, van Oers JM, Vogt T, Landthaler M, Stoehr R, Blaszyk H, Hofstaedter F, Zwarthoff EC, Hartmann A: Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J Clin Invest. 2006 Aug;116(8):2201-2207.</reference_text>
      <pubmed_id>16841094</pubmed_id>
    </reference>
    <reference>
      <reference_text>Rohmann E, Brunner HG, Kayserili H, Uyguner O, Nurnberg G, Lew ED, Dobbie A, Eswarakumar VP, Uzumcu A, Ulubil-Emeroglu M, Leroy JG, Li Y, Becker C, Lehnerdt K, Cremers CW, Yuksel-Apak M, Nurnberg P, Kubisch C, Schlessinger J, van Bokhoven H, Wollnik B: Mutations in different components of FGF signaling in LADD syndrome.  Nat Genet. 2006 Apr;38(4):414-7. Epub 2006 Feb 26.</reference_text>
      <pubmed_id>16501574</pubmed_id>
    </reference>
    <reference>
      <reference_text>Arnaud-Lopez L, Fragoso R, Mantilla-Capacho J, Barros-Nunez P: Crouzon with acanthosis nigricans. Further delineation of the syndrome.  Clin Genet. 2007 Nov;72(5):405-10.</reference_text>
      <pubmed_id>17935505</pubmed_id>
    </reference>
    <reference>
      <reference_text>Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, Edkins S, O'Meara S, Vastrik I, Schmidt EE, Avis T, Barthorpe S, Bhamra G, Buck G, Choudhury B, Clements J, Cole J, Dicks E, Forbes S, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jenkinson A, Jones D, Menzies A, Mironenko T, Perry J, Raine K, Richardson D, Shepherd R, Small A, Tofts C, Varian J, Webb T, West S, Widaa S, Yates A, Cahill DP, Louis DN, Goldstraw P, Nicholson AG, Brasseur F, Looijenga L, Weber BL, Chiew YE, DeFazio A, Greaves MF, Green AR, Campbell P, Birney E, Easton DF, Chenevix-Trench G, Tan MH, Khoo SK, Teh BT, Yuen ST, Leung SY, Wooster R, Futreal PA, Stratton MR: Patterns of somatic mutation in human cancer genomes.  Nature. 2007 Mar 8;446(7132):153-8.</reference_text>
      <pubmed_id>17344846</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
  </metabolite_references>
</protein>
